CCXI
Income statement / Annual
Last year (2021), ChemoCentryx, Inc.'s total revenue was $32.22 M,
a decrease of 50.34% from the previous year.
In 2021, ChemoCentryx, Inc.'s net income was -$129.06 M.
See ChemoCentryx, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
| Period Ended |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
12/31/2012 |
| Operating Revenue |
$32.22 M |
$64.89 M |
$35.95 M |
$42.88 M |
$82.50 M |
$11.44 M |
$0.00 |
$0.00 |
$6.06 M |
$5.42 M |
| Cost of Revenue |
$302.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$31.92 M
|
$64.89 M
|
$35.95 M
|
$42.88 M
|
$82.50 M
|
$11.44 M
|
$0.00
|
$0.00
|
$6.06 M
|
$5.42 M
|
| Gross Profit Ratio |
0.99
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
1
|
1
|
| Research and Development Expenses |
$82.99 M
|
$77.88 M
|
$70.28 M
|
$62.74 M
|
$49.50 M
|
$37.95 M
|
$33.18 M
|
$33.82 M
|
$33.54 M
|
$34.57 M
|
| General & Administrative Expenses |
$0.00
|
$42.19 M
|
$24.16 M
|
$20.41 M
|
$16.51 M
|
$14.71 M
|
$14.51 M
|
$13.58 M
|
$11.63 M
|
$10.48 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$78.85 M
|
$42.19 M
|
$24.16 M
|
$20.41 M
|
$16.51 M
|
$14.71 M
|
$14.51 M
|
$13.58 M
|
$11.63 M
|
$10.48 M
|
| Other Expenses |
$302.00 K
|
$0.00
|
-$176.00 K
|
$0.00
|
$0.00
|
-$500.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$162.14 M
|
$120.07 M
|
$94.26 M
|
$83.15 M
|
$66.00 M
|
$52.16 M
|
$47.69 M
|
$47.40 M
|
$45.18 M
|
$45.05 M
|
| Cost And Expenses |
$162.45 M
|
$120.07 M
|
$94.26 M
|
$83.15 M
|
$66.00 M
|
$52.16 M
|
$47.69 M
|
$47.40 M
|
$45.18 M
|
$45.05 M
|
| Interest Income |
$859.00 K
|
$2.46 M
|
$4.96 M
|
$3.53 M
|
$1.37 M
|
$757.00 K
|
$384.00 K
|
$494.00 K
|
$501.00 K
|
$533.00 K
|
| Interest Expense |
-$2.70 M
|
$2.64 M
|
$2.15 M
|
$1.22 M
|
$4.00 K
|
$0.00
|
$0.00
|
$24.00 K
|
$59.00 K
|
$794.00 K
|
| Depreciation & Amortization |
$3.14 M
|
$797.00 K
|
$1.64 M
|
$512.00 K
|
$418.00 K
|
$348.00 K
|
$477.00 K
|
$543.00 K
|
$576.00 K
|
$592.00 K
|
| EBITDA |
-$131.31 M |
-$51.92 M |
-$51.70 M |
-$36.23 M |
$18.28 M |
-$39.62 M |
-$46.83 M |
-$46.36 M |
-$38.04 M |
-$38.51 M |
| EBITDA Ratio |
-4.07
|
-0.8
|
-1.44
|
-0.85
|
0.22
|
-3.46
|
0
|
0
|
-6.28
|
-7.11
|
| Operating Income Ratio |
-4.17
|
-0.85
|
-1.62
|
-0.94
|
0.2
|
-3.56
|
0
|
0
|
-6.45
|
-7.31
|
| Total Other Income/Expenses Net |
-$1.84 M
|
-$179.00 K
|
$2.81 M
|
$2.30 M
|
$1.37 M
|
$757.00 K
|
$384.00 K
|
$470.00 K
|
$442.00 K
|
-$261.00 K
|
| Income Before Tax |
-$131.76 M
|
-$55.36 M
|
-$55.49 M
|
-$37.97 M
|
$17.86 M
|
-$39.96 M
|
-$47.31 M
|
-$46.93 M
|
-$38.67 M
|
-$39.89 M
|
| Income Before Tax Ratio |
-4.09
|
-0.85
|
-1.54
|
-0.89
|
0.22
|
-3.49
|
0
|
0
|
-6.38
|
-7.36
|
| Income Tax Expense |
-$2.70 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$384.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$129.06 M
|
-$55.36 M
|
-$55.49 M
|
-$37.97 M
|
$17.86 M
|
-$39.96 M
|
-$47.31 M
|
-$46.93 M
|
-$38.67 M
|
-$39.89 M
|
| Net Income Ratio |
-4.01
|
-0.85
|
-1.54
|
-0.89
|
0.22
|
-3.49
|
0
|
0
|
-6.38
|
-7.36
|
| EPS |
-1.96 |
-0.84 |
-0.98 |
-0.76 |
0.37 |
-0.86 |
-1.08 |
-1.08 |
-0.95 |
-1.13 |
| EPS Diluted |
-1.96 |
-0.84 |
-0.98 |
-0.76 |
0.36 |
-0.86 |
-1.08 |
-1.08 |
-0.95 |
-1.13 |
| Weighted Average Shares Out |
$65.69 M
|
$65.69 M
|
$56.90 M
|
$49.81 M
|
$48.41 M
|
$46.43 M
|
$43.89 M
|
$43.28 M
|
$40.92 M
|
$35.41 M
|
| Weighted Average Shares Out Diluted |
$65.69 M
|
$65.69 M
|
$56.90 M
|
$49.81 M
|
$49.62 M
|
$46.43 M
|
$43.89 M
|
$43.28 M
|
$40.92 M
|
$35.41 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
